09/27/2004 01 FC:1814

BEST AVAILABLE COPY

PTC/S8/28 (U8-03)
Approved for use through 07/31/2006. OMS 0851-0031
U.S. Patent and Tredemark Office; U.S. DEPARTMENT OF COMMERCE
d to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING		Docket Number (Optional)
REJECTION OVER A PRIOR PAT		CV-31583
In re Application of: Jean-Pierre Pascault		
Application No.: 09/937,551		
Filed: December 12, 2001	and the Thereof in Coverince on	d Marediaa Deaducto
For: Crosslinked Acrylic Microparticles, Method for the Production There		
The owner*, Crey Valley, S.A. of 100 disclaims, except as provided below, the terminal part of the state which would extend beyond the expiration date of the full-state shortened by any terminal disclaimer, of prior Patent No. 6.586, so granted on the instant application shall be enforceable only commonly owned. This agreement runs with any patent granted its successors or assigns.	utory term defined in 35 U.S.C. 1937 The owner here 1937	on the instant application, 154 and 173, as presently by agrees that any patent it and the prior patent are
In making the above disclaimsr, the owner does not disapplication that would extend to the expiration date of the full prior patent, as presently shortened by any terminal disclaim maintenance fee, is held unenforceable, is found invalid by a whole or terminally disclaimed under 37 CFR 1.321, has all claims in any manner terminated prior to the expiration of its fudisclaimer.	statutory term as defined in 35 ner, in the event that it later: e court of competent jurisdiction, ims canceled by a reexamination	U.S.C. 154 and 173 of the expires for failure to pay a is statutorily disclaimed in n certificate, is reissued, or
Check either box 1 or 2 below, if appropriate.		
1. For submissions on behalf of an organization (e.g., con etc.), the undersigned is empowered to act on behalf or	poration, partnership, university, f the organization.	government agency,
I hereby declare that all statements made herein of my information and belief are believed to be true; and further that it false statements and the like so made are punishable by fine of the United States Code and that such willful false statements ressued thereon.	hese statements were made with In imprisonment, or both, under t	the knowledge that willful Section 1001 of Title 18 of
2. The undersigned is an attorney or egent of record.	Clar Chyling	9/22/64
	Signature	Date
	Alan E. We	gner
ISELLMAN 00000004 232053 09937551 .	Typed or printed name	
110,00 DA	414-273-2100	
Telephone Number		
Terminal disclaimer fee under 37 CFR 1.20(d) included. WARNING: Information on this form may become ple included on this form. Provide credit card information.	oublic. Credit card information sh mation and authorization on PTO-	ould not 2038.
"Statement under 37 CFR 3.73(b) is required if terminal discialmer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.		

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to precess) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradsmark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. GEND TO: Commissioner for Patients, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-500-PTO-0199 and select option 2.